Parametric Portfolio Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Parametric Portfolio Associates’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.36M	Sell	209,062 -78,329	-27%	-$1.03M	﹤0.01%	2332
2021 Q4	$4.51M	Buy	287,391 +25,937	+10%	+$452K	﹤0.01%	1940
2021 Q3	$4.48M	Sell	261,454 -4,737	-2%	-$83K	﹤0.01%	1907
2021 Q2	$5.73M	Buy	266,191 +10,744	+4%	+$192K	﹤0.01%	1762
2021 Q1	$3.84M	Buy	255,447 +75,838	+42%	+$1.23M	﹤0.01%	2345
2020 Q4	$2.36M	Buy	179,609 +88,723	+98%	+$1.07M	﹤0.01%	2556
2020 Q3	$878K	Sell	90,886 -7,592	-8%	-$81.1K	﹤0.01%	2999
2020 Q2	$1.13M	Buy	98,478 +32,477	+49%	+$368K	﹤0.01%	2854
2020 Q1	$684K	Sell	66,001 -105,666	-62%	-$1.31M	﹤0.01%	2994
2019 Q4	$2.82M	Buy	171,667 +49,676	+41%	+$751K	﹤0.01%	2461
2019 Q3	$1.62M	Buy	121,991 +33,077	+37%	+$461K	﹤0.01%	2772
2019 Q2	$1.25M	Buy	88,914 +28,135	+46%	+$448K	﹤0.01%	2939
2019 Q1	$1.12M	Sell	60,779 -62,942	-51%	-$1.43M	﹤0.01%	2974
2018 Q4	$3.23M	Buy	123,721 +101,431	+455%	+$2.38M	﹤0.01%	2236
2018 Q3	$512K	Buy	22,290 +4,671	+27%	+$95.4K	﹤0.01%	3406
2018 Q2	$336K	Buy	+17,619	New	+$295K	﹤0.01%	3513
2018 Q1	–	Sell	-36,241	Closed	-$551K	–	3968
2017 Q4	$551K	Sell	36,241 -29,335	-45%	-$435K	﹤0.01%	3277
2017 Q3	$1.17M	Buy	65,576 +28,657	+78%	+$480K	﹤0.01%	2939
2017 Q2	$602K	Buy	36,919 +12,769	+53%	+$184K	﹤0.01%	3252
2017 Q1	$338K	Sell	24,150 -1,500	-6%	-$21.4K	﹤0.01%	3386
2016 Q4	$409K	Buy	+25,650	New	+$412K	﹤0.01%	3288
2015 Q1	–	Sell	-19,932	Closed	-$285K	–	4005
2014 Q4	$285K	Sell	19,932 -815	-4%	-$9.64K	﹤0.01%	3597
2014 Q3	$215K	Sell	20,747 -5,449	-21%	-$71.4K	﹤0.01%	3591
2014 Q2	$424K	Buy	26,196 +328	+1%	+$4.37K	﹤0.01%	3302
2014 Q1	$420K	Buy	25,868 +7,149	+38%	+$102K	﹤0.01%	3266
2013 Q4	$232K	Buy	18,719 +4,789	+34%	+$48.1K	﹤0.01%	3549
2013 Q3	$153K	Buy	13,930 +249	+2%	+$2.66K	﹤0.01%	3663
2013 Q2	$111K	Buy	+13,681	New	+$92.1K	﹤0.01%	3586

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parametric Portfolio Associates's VNDA Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Vanda Pharmaceuticals (VNDA) stake by 27% in Q1 2022, selling an estimated $1.03M and leaving 209,062 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Parametric Portfolio Associates first reported a position in VNDA in Q2 2013 and has held it in 28 quarters since. The position peaked at $5.73M in Q2 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

Parametric Portfolio Associates held 209,062 shares of Vanda Pharmaceuticals worth $2.36M as of Q1 2022.
Parametric Portfolio Associates sold 78,329 Vanda Pharmaceuticals shares in Q1 2022, an estimated $1.03M.
Vanda Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2332 holding.
Parametric Portfolio Associates first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 28 quarters since.
Parametric Portfolio Associates's Vanda Pharmaceuticals position peaked at $5.73M in Q2 2021.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.